New imaging agent shows promise for spotting prostate cancer
NCT ID NCT04838626
First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 30 times
Summary
This study tested a new PET imaging agent called [18F]CTT1057 to see how well it can find prostate cancer tumors. 195 men with high-risk prostate cancer who were scheduled for surgery received the PET scan, and the results were compared to tissue samples taken during surgery. The goal was to see if the scan could accurately detect cancer in the prostate and nearby lymph nodes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Explorer Molecular Imaging center
Sacramento, California, 95816, United States
-
Novartis Investigative Site
Marseille, 13273, France
-
Novartis Investigative Site
Nîmes, 30029, France
-
Novartis Investigative Site
Pierre-Bénite, 69495, France
-
Novartis Investigative Site
Toulouse, 31054, France
-
Novartis Investigative Site
Toulouse, 31059, France
-
Novartis Investigative Site
Bergamo, BG, 24127, Italy
-
Novartis Investigative Site
Milan, MI, 20132, Italy
-
Novartis Investigative Site
Milan, MI, 20141, Italy
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Bellinzona, 6500, Switzerland
-
Novartis Investigative Site
Geneva, 1211, Switzerland
Conditions
Explore the condition pages connected to this study.